Search
Chipscreen Biosciences Receives FDA Acceptance for CS231295 Clinical Trial Application
2025-07-01 /
Read about 0 minute
Author：小编
Chipscreen Biosciences' wholly-owned subsidiary has received a formal acknowledgment from the U.S. Food and Drug Administration (FDA) regarding its clinical trial application for CS231295, a proprietary drug specifically designed to target advanced solid tumors. CS231295 stands out as a brain-penetrating Aurora B selective inhibitor, marking a unique position in the global landscape where no similar drugs have yet entered clinical trials. Provided that no objections are raised by the FDA or formal approval is granted within the 30-day period, the company intends to proceed with the clinical trials of CS231295 as per its scheduled plan.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
